Merck KGaA (MRK) Given a €100.00 Price Target by JPMorgan Chase & Co. Analysts

JPMorgan Chase & Co. set a €100.00 ($116.28) price target on Merck KGaA (FRA:MRK) in a research note published on Monday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

Several other analysts also recently issued reports on the stock. Deutsche Bank set a €97.00 ($112.79) price objective on shares of Merck KGaA and gave the company a neutral rating in a research report on Thursday, May 9th. Nord/LB set a €80.00 ($93.02) price objective on shares of Merck KGaA and gave the company a sell rating in a research report on Thursday, January 24th. HSBC set a €96.00 ($111.63) price objective on shares of Merck KGaA and gave the company a neutral rating in a research report on Monday, March 11th. Sanford C. Bernstein set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the company a buy rating in a research report on Thursday, March 7th. Finally, Goldman Sachs Group set a €95.00 ($110.47) price objective on shares of Merck KGaA and gave the company a neutral rating in a research report on Tuesday, February 12th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of €101.05 ($117.50).

Shares of FRA:MRK opened at €91.66 ($106.58) on Monday. Merck KGaA has a 52-week low of €76.60 ($89.07) and a 52-week high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Article: Why Invest in Dividend Achievers?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.